Literature DB >> 16857811

ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.

Daniel Steinbach1, Jean-Pierre Gillet, Axel Sauerbrey, Bernd Gruhn, Kristin Dawczynski, Vincent Bertholet, Françoise de Longueville, Felix Zintl, Jose Remacle, Thomas Efferth.   

Abstract

BACKGROUND: A major issue in the treatment of acute myeloid leukemia (AML) is resistance to chemotherapeutic drugs. Multidrug resistance can be caused by ATP-binding cassette (ABC) transporters that function as drug efflux pumps. The majority of these proteins have not yet been examined in malignant diseases. EXPERIMENTAL
DESIGN: A newly developed microarray for the simultaneous quantification of 38 ABC transporter genes and Taqman real-time PCR was used to analyze the expression of ABC transporters in pediatric AML and healthy bone marrow. Small interfering RNA was used to verify the role of ABCA3 in drug resistance.
RESULTS: Using the microarray, we identified four new ABC transporters, which were overexpressed in many AML samples compared with healthy bone marrow: ABCA2, ABCA3, ABCB2, and ABCC10. The overexpression of these four genes was verified by real-time PCR in 42 samples from children with AML and 18 samples of healthy bone marrow. The median expression of ABCA3 was three times higher in 21 patients who had failed to achieve remission after the first course of chemotherapy than in a well-matched group of 21 patients who had achieved remission at this stage (P = 0.023). Incubation of cell lines with a number of different cytostatic drugs induced an up-regulation of ABCA3. Down-regulation of ABCA3 by small interfering RNA sensitized cells to doxorubicin.
CONCLUSION: Our results show that ABCA2, ABCA3, ABCB2, and ABCC10 are overexpressed in childhood AML compared with healthy bone marrow. ABCA3 is the most likely transporter to cause drug resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857811     DOI: 10.1158/1078-0432.CCR-05-2587

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

Review 1.  Drug resistance: still a daunting challenge to the successful treatment of AML.

Authors:  Brian C Shaffer; Jean-Pierre Gillet; Chirayu Patel; Maria R Baer; Susan E Bates; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-03-11       Impact factor: 18.500

2.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Authors:  Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Miguel Marino; Lisa J Green; Meena I Vora; Chirayu Patel; Josiah N Orina; Tatiana A Eliseeva; Vineet Singal; Raji Padmanabhan; Ben Davidson; Ram Ganapathi; Anil K Sood; Bo R Rueda; Suresh V Ambudkar; Michael M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-08       Impact factor: 11.205

3.  ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients.

Authors:  Christophe Marzac; Edith Garrido; Ruoping Tang; Fanny Fava; Pierre Hirsch; Cinzia De Benedictis; Elise Corre; Simona Lapusan; Jean-Yves Lallemand; Jean-Pierre Marie; Eric Jacquet; Ollivier Legrand
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

4.  ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.

Authors:  Bjoern Chapuy; Melanie Panse; Ulf Radunski; Raphael Koch; Dirk Wenzel; Nobuya Inagaki; Detlef Haase; Lorenz Truemper; Gerald G Wulf
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

5.  Increased Risk of Interstitial Lung Disease in Children with a Single R288K Variant of ABCA3.

Authors:  Thomas Wittmann; Sabrina Frixel; Stefanie Höppner; Ulrike Schindlbeck; Andrea Schams; Matthias Kappler; Jan Hegermann; Christoph Wrede; Gerhard Liebisch; Anne Vierzig; Angela Zacharasiewicz; Matthias Volkmar Kopp; Christian F Poets; Winfried Baden; Dominik Hartl; Anton H van Kaam; Peter Lohse; Charalampos Aslanidis; Ralf Zarbock; Matthias Griese
Journal:  Mol Med       Date:  2016-02-26       Impact factor: 6.354

Review 6.  ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target.

Authors:  Warren Davis; Kenneth D Tew
Journal:  Biochem Pharmacol       Date:  2017-12-06       Impact factor: 5.858

7.  Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.

Authors:  Thiha Aung; Bjoern Chapuy; Daniel Vogel; Dirk Wenzel; Martin Oppermann; Marlen Lahmann; Toni Weinhage; Kerstin Menck; Timo Hupfeld; Raphael Koch; Lorenz Trümper; Gerald G Wulf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-25       Impact factor: 11.205

Review 8.  Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.

Authors:  M Mimeault; R Hauke; S K Batra
Journal:  Clin Pharmacol Ther       Date:  2007-09-05       Impact factor: 6.875

9.  ABC transporters in cancer: more than just drug efflux pumps.

Authors:  Jamie I Fletcher; Michelle Haber; Michelle J Henderson; Murray D Norris
Journal:  Nat Rev Cancer       Date:  2010-01-15       Impact factor: 60.716

10.  Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.

Authors:  Josiah N Orina; Anna Maria Calcagno; Chung-Pu Wu; Sudhir Varma; Joanna Shih; Min Lin; Gabriel Eichler; John N Weinstein; Yves Pommier; Suresh V Ambudkar; Michael M Gottesman; Jean-Pierre Gillet
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.